Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Abstract

Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).

1 . A method for inhibiting tumor progression in a human patient with cancer, comprising administering human CRF and bevacizumab (Avastin®) to said patient; wherein said administering CRF comprises administering CRF to said patient subcutaneously at least once per day. 
     
     
         2 . The method of  claim 1 , wherein the cancer is one or more selected from the group consisting of bladder cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, liver cancer, lung cancer, small cell and non-small cell lung cancer, melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, osteosarcoma, skin cancer, squamous cell carcinoma, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, mesothelioma, cholangiocarcinoma, leiomyosarcoma, liposarcoma, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, salivary gland cancer, small cell lung cancer, spindle cell carcinoma, brain tumor, metastatic brain tumor, glioblastoma, glioma, ependymoma, astrocytoma, medulloblastoma, neuroglioma, oligodendroglioma or meningioma. 
     
     
         3 . The method of  claim 2 , wherein the cancer is metastatic. 
     
     
         4 . The method of  claim 1 , wherein the method further comprises monitoring tumor progression in the human. 
     
     
         5 . The method of  claim 1 , wherein said administering CRF comprises administering CRF in a dose between 1 μg/kg to 100 μg/kg of body weight of the patient. 
     
     
         6 . The method of  claim 1 , wherein said administering CRF comprises administering CRF in a dose of about 1 to about 4 mg. 
     
     
         7 . The method of  claim 1 , wherein said administering CRF comprises administering CRF in a dose of about 1 mg. 
     
     
         8 . The method of  claim 1 , wherein said administering CRF comprises administering CRF twice daily to said patient. 
     
     
         9 . The method of  claim 1 , wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of 2 weeks or more. 
     
     
         10 . The method of  claim 1 , wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of one month or more. 
     
     
         11 . The method of  claim 1 , wherein said administering CRF comprises administering CRF to said patient at least once a day for a period of 3 months or more. 
     
     
         12 . The method of  claim 1 , wherein bevacizumab (Avastin®) is administered in a dose between 5 mg/kg and 15 mg/kg of body weight of the patient. 
     
     
         13 . The method of  claim 1 , wherein bevacizumab (Avastin®) is administered in a dose of 10 mg/kg of body weight of the patient. 
     
     
         14 . The method of  claim 1 , wherein said administering bevacizumab (Avastin®) is administered to the patient once a week, every two weeks or every three weeks. 
     
     
         15 . A container for a pharmaceutical composition comprising CRF and a pharmaceutical label, wherein the pharmaceutical label indicates that the CRF is to be administered with bevacizumab (Avastin®) for treatment of cancer in a human patient. 
     
     
         16 . The container of  claim 15 , wherein the label further indicates that the dose of CRF administered is between 1 μg/kg to 100 μg/kg of body weight of the human patient, or about 1 mg to about 4 mg. 
     
     
         17 . The container of  claim 15 , wherein the label further indicates that CRF is administered subcutaneously to said patient at least once a day. 
     
     
         18 . The container of  claim 15 , wherein the label further indicates that bevacizumab (Avastin®) is administered in a dose between 5 mg/kg and 15 mg/kg of body weight of the patient. 
     
     
         19 . The container of  claim 15 , wherein the label further indicates that bevacizumab (Avastin®) is administered in a dose of 10 mg/kg of body weight of the patient. 
     
     
         20 . The container of  claim 15 , wherein the label further indicates that the cancer is bladder cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, liver cancer, lung cancer, small cell and non-small cell lung cancer, melanoma, myeloma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, osteosarcoma, skin cancer, squamous cell carcinoma, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, mesothelioma, cholangiocarcinoma, leiomyosarcoma, liposarcoma, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, salivary gland cancer, small cell lung cancer, spindle cell carcinoma, brain tumor, metastatic brain tumor, glioblastoma, glioma, ependymoma, astrocytoma, medulloblastoma, neuroglioma, oligodendroglioma or meningioma.